| Literature DB >> 25634208 |
David M Neskey1, Abdullah A Osman2, Thomas J Ow3, Panagiotis Katsonis4, Thomas McDonald5, Stephanie C Hicks6, Teng-Kuei Hsu4, Curtis R Pickering2, Alexandra Ward2, Ameeta Patel2, John S Yordy7, Heath D Skinner8, Uma Giri9, Daisuke Sano10, Michael D Story11, Beth M Beadle12, Adel K El-Naggar13, Merrill S Kies14, William N William14, Carlos Caulin2, Mitchell Frederick2, Marek Kimmel5, Jeffrey N Myers15, Olivier Lichtarge4.
Abstract
TP53 is the most frequently altered gene in head and neck squamous cell carcinoma, with mutations occurring in over two-thirds of cases, but the prognostic significance of these mutations remains elusive. In the current study, we evaluated a novel computational approach termed evolutionary action (EAp53) to stratify patients with tumors harboring TP53 mutations as high or low risk, and validated this system in both in vivo and in vitro models. Patients with high-risk TP53 mutations had the poorest survival outcomes and the shortest time to the development of distant metastases. Tumor cells expressing high-risk TP53 mutations were more invasive and tumorigenic and they exhibited a higher incidence of lung metastases. We also documented an association between the presence of high-risk mutations and decreased expression of TP53 target genes, highlighting key cellular pathways that are likely to be dysregulated by this subset of p53 mutations that confer particularly aggressive tumor behavior. Overall, our work validated EAp53 as a novel computational tool that may be useful in clinical prognosis of tumors harboring p53 mutations. ©2015 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25634208 PMCID: PMC4383697 DOI: 10.1158/0008-5472.CAN-14-2735
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701